Entecavir
- Generic Name
- Entecavir
- Brand Names
- Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C12H15N5O3
- CAS Number
- 142217-69-4
- Unique Ingredient Identifier
- NNU2O4609D
- Background
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...
- Indication
For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
- Associated Therapies
- -
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT00922207
- Locations
- 🇨🇳
National Taiwan Uni Hospital; Gastro-Enterology Dept., Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital; Gastroenterology Division, Taipei, Taiwan
🇨🇳Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine, Kaohsiung, Taiwan
Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 184
- Registration Number
- NCT00877760
- Locations
- 🇷🇴
Nat. Institute of inf. Disease, Bucharest, Romania
🇵🇱CMUMU, Bydgoszcz, Poland
🇵🇱WAMED, Zawiercie, Poland
Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00824707
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 462
- Registration Number
- NCT00823550
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Suboptimal Responders to Adefovir Switching to Entecavir
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 228
- Registration Number
- NCT00718887
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Pacific Health Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT00704106
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸San Jose Gastroenterology, San Jose, California, United States
🇺🇸Asian Village Medical Clinic, Chicago, Illinois, United States
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00663182
- Locations
- 🇨🇳
Shanghai changzheng Hospital, Shanghai, Shanghai, China
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00637663
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT00625560
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT00625339
- Locations
- 🇰🇷
Pusan National University School of Medicine, Busan, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.